Biocytogen’s RenMab™ Mouse is featured on Fiercebiotech.com today. Read the full article here.
RenMab™ Mouse highlights:
- Developed upon Biocytogen’s unique Mb-scale chromosome engineering technology
- Variable regions of heavy chain and k light chain are replaced by human counterparts in situ
- Constant region is retained to ensure proper B cell development
- Normal response to immunization
FierceBiotech and its family of publications provide end-to-end coverage of biotech and medtech, from pre-clinical science through clinical testing and regulatory approval—and all the seed funding, venture capital, licensing deals, IPOs and M&A that happen along the way. We track tiny, virtual startups and the biggest of Big Pharma, highlighting the accomplishments and acknowledging the defeats that all of them experience on their way to market with a new therapy or device. The FierceBiotech team transcends the daily as well, with comprehensive coverage of key medical meetings plus special reports that highlight up-and-comers and shed new light on industry heavyweights.